GENE ONLINE|News &
Apnimed Secures $150 Million Financing for Commercial Launch of Sleep Apnea Treatment AD109
Apnimed has secured up to $150 million in debt financing from HealthCare Royalty Partners. The funding is intended to support the planned commercial launch of AD109, a treatment developed by Apnimed for obstructive sleep apnea. The agreement provides Apnimed with access to significant financial resources as it prepares for the next phase of its product rollout.
The financing arrangement includes provisions that will allow Apnimed to draw funds in stages, depending on specific milestones related to the development and commercialization of AD109. HealthCare Royalty Partners specializes in providing capital to healthcare companies, particularly those focused on innovative treatments and therapies. This partnership reflects a strategic effort by Apnimed to ensure adequate funding for its operations as it moves toward bringing AD109 to market.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: April 6, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Haloperidol Identified as Potential Treatment to Improve Muscle Function and Neuroprotection in Spinal Muscular Atrophy
2026-04-13
Advanced CRISPR System Using Al3Cas12f Enzyme Achieves 90 Percent Gene Editing Efficiency in Human Cells
2026-04-13
Researchers Map Pain-Sensing Neurons to Identify Proteins Linked to Chronic Inflammatory Pain
2026-04-13
FDA Grants Full Approval to Travere Therapeutics’ FILSPARI as First Medication for Treating FSGS
2026-04-13
EVENT
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
